Pelvic Organ ProlapseEVeRLASTNCT04329715
Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse
A study testing Expedited postoperative activity instructions and Standard postoperative activity restructions in people with Pelvic Organ Prolapse, run by Duke University at 1 site in United States.
Trial summary
The objective of the EVeRLAST study is to determine whether expedited resumption of postoperative activity levels is non-inferior to standard activity restrictions with respect to short-term anatomic prolapse outcomes. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pelvic Organ Prolapse
- What is being tested?
- Expedited postoperative activity instructions and Standard postoperative activity restructions
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 123 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2020to 15 Feb 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Stage II-IV pelvic organ prolapse
- Bothersome bulge symptoms
- At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form
- English-speaking
- Undergoing treatment of prolapse
- Surgery occurring at least 7 days from date of randomization (to allow for collection of at least 7 days of preoperative accelerometer data)
- Able and willing to follow up at 3 months for in-office exam
Who cannot join
- Enrollment in another research study of pelvic organ prolapse
- Concomitant non-urogynecologic surgery
- Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Medical Center
Durham, North Carolina, 27710
About this study
The objective of the EVeRLAST study is to determine whether expedited resumption of postoperative activity levels is non-inferior to standard activity restrictions with respect to short-term anatomic prolapse outcomes. We hypothesize that immediate resumption of physical activities as tolerated will result in noninferior surgical outcomes following prolapse surgery when compared to standard postoperative activity restrictions.
Participants will be enrolled and randomized at their preoperative clinic visit to one of two treatment arms:
Read more
Arm 1: Standard instructions (no heavy lifting over 10lbs for 6 weeks; return to work at 4 weeks for sedentary work and 6 weeks for manual labor) Arm 2: Liberal instructions (no restrictions; resume activities and work as soon as able)
We will also collect subjective and objective measures of pre- and postoperative physical activity, through the use of patient-reported physical activity assessments and wrist-worn accelerometers. Accelerometer data will be collected at the preoperative, 2-week-postoperative, and 6-week-postoperative time points. Accelerometer data will also be used to calculate time to resumption of normal activities, defined as time at which a patient resumes greater than 90% of her baseline preoperative level of physical activity. We will additionally be collecting data on relevant patient-reported outcomes of pelvic floor symptom severity, health-related quality of life measures, postoperative pain, time to return to work (where relevant), and patient global impression of improvement. Postoperative anatomic assessments will be performed at 6 weeks and 3 months postoperatively by blinded study personnel
Read the detailed description
Specific aim 1: Determine if liberal (ad lib) resumption of postoperative activity levels is non-inferior to standard restrictions with regards to short-term anatomic and symptomatic outcome, as measured by maximum pelvic organ prolapse support loss ('SLmax') and the Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months. (Co-primary outcome)
Specific aim 2: Compare postoperative "Recovery Time" and physical function between women instructed to resume their activity levels ad lib versus women instructed to restrict activity levels. "Recovery Time," defined as the postoperative day at which the patient resumes 90% of her baseline activity levels will be objectively measured using the Actigraph accelerometer.8 ,9 Physical function will be measured with the 6-minute walk, chair stand tests, and through patient-reported outcome measures. (exploratory outcome)
Specific aim 3: Compare timing of return-to-work and health-related QOL in women instructed to resume activity levels and return to work ad lib versus restrict their activity levels (exploratory outcome)
Eligible participants will first be briefly explained regarding the research study. If interested, will then complete the informed consent process. She will first be asked to complete the International Physical Activity Short Form to confirm study eligibility. For study eligibility, participants must at least report a baseline of 725 MET-minutes per week of physical activity according to the IPAQ-SF, which is consistent with the lowest quartile of activity among elderly women. If she reports greater than 725 MET-minutes per week of physical activity, she will undergo the remainder of baseline assessments. If she reports less than 725 MET-minutes per week of physical activity, she will be explained that she does not meet the activity level criteria for completion of the study at this time. She will then be asked to complete a series of baseline questionnaires (demographics, past medical history, POPDI, AAS, PROMIS, PFDI, PFIQ). She will also undergo a baseline POPQ exam and tests of physical function, including the 6-minute walk test and chair stand test.
A sealed envelope will then be opened by the research coordinator (or study investigator) in front of the patient indicating the patient's study allocation. The packet will also include an accelerometer which the patient will be instructed to wear for a 7-day period preoperatively. However, to ensure that participants are not given an accelerometer too far in advance from her surgery (as at times surgery may be scheduled remotely from the initial decision to proceed with surgery which would potentially result in too many accelerometers being out of circulation), the envelope containing study allocation and accelerometers may alternatively be provided at the preoperative "Surgical Workup" visit once the surgery is scheduled and at a date no greater than 3 weeks from the planned surgery. If a participant will be undergoing surgery at an interval greater than 1 week from the initial receipt of the accelerometer, she will only be required to wear the accelerometer for 1 week prior to the surgery. Patients will be given an opportunity to ask any questions regarding postoperative activity instructions to research personnel or nurses at the time of study enrollment and at any point prior to her surgery. Patients will be notified, prior to providing consent, that her primary surgeon will remain blinded as to her treatment allocation until completion of her study participation.
Any questions related to surgical recovery which arise preoperatively will be addressed by nurses and research personnel not involved in the patient's intraoperative decision-making. Postoperatively, fellow and attending surgeons will only be unblinded if necessary to address any acute postoperative issues. Patients will also be provided with a duplicate set of postoperative set of activity instructions on the day of her surgery upon discharge which will be entered in the patient's electronic chart by study personnel on the day of her surgery as a modification to the standard postoperative discharge instructions.
The patient will wear the activity tracker for 6 weeks postoperatively. At the 1-week postoperative time point, patient reminder phone calls will be made to remind the patient to wear and charge the activity tracker (whose battery life is 25 days). She will also be asked to provide a count of the number of narcotic pills she has left remaining at this time. She will follow-up for a routine postoperative visit with her primary surgeon at which point a routine 6-week postoperative POPQ will be performed. Accelerometers will be returned at this visit.
She will then follow up for a separate research visit at 3 months postoperatively. At this time, the patient will complete all follow-up activity, symptom, and HRQOL questionnaires including the: Activities Assessment Scale, Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and the PROMIS short form subscales of physical function, anxiety, depression, fatigue, satisfaction with social role, and pain interference. A six-minute walk and chair stand test will be administered by trained research personnel in the clinic. She will additionally be inquired regarding timing of return to work. A POPQ will also be performed at this time by a blinded provider NOT involved in the patient's index surgery.
- Conditions
- Pelvic Organ Prolapse
- Being tested
- Expedited postoperative activity instructions, Standard postoperative activity restructions
- Medical subject headings
- Pelvic Organ Prolapse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Expedited postoperative activity instructionsBehavioural
Ad lib postoperative activity and return to work recommendations
Standard postoperative activity restructionsBehavioural
Standard conservative postoperative activity and return to work recommendations
| Study group | Role | What they receive |
|---|---|---|
| Expedited instructions | Experimental | Not described Receives: Behavioral: Expedited postoperative activity instructions |
| Restricted instructions | Active comparator | Not described Receives: Behavioral: Standard postoperative activity restructions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum support loss "SLMax"
Most distal point of pelvic organ support (in centimeters) based on Pelvic Organ Prolapse Quantification system
Measured: 3 months
Prolapse symptoms
Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months
Measured: 3 months
Secondary outcomes (11)
Recovery time
Time to resumption of >90% of baseline activity, measured with ActiGraph accelerometer worn pre- and 6 weeks postoperatively
Measured: 6 weeks
Health related quality of life (HRQOL)
HRQOL as measured by the PROMIS short form subscales of physical function, anxiety, depression, fatigue, satisfaction with social role, and pain interference
Measured: 3 months
Physical function
Functional aerobic capacity as measured by the 6 Minute Walk Test
Measured: 3 months
Physical function
Functional strength as measured by the Chair Stand Test
Measured: 3 months
Time to return to work
Postoperative day at which patient returned to work
Measured: 3 months
Postoperative opioid requirement
Opioid pill count
Measured: 2 weeks
Pelvic floor symptom severity
Measured by the Pelvic Floor Distress Inventory-20
Measured: 3 months
Pelvic floor symptom severity
Measured by the Pelvic Floor Impact Questionnaire-7
Measured: 3 months
Functional activity
As measured by the Activities Assessment Scale
Measured: 3 months
Patient satisfaction
As measured by Patient Global Impression of Improvement
Measured: 3 months
Postoperative morbidity
Postoperative morbidity following surgery
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2020
- Study start1 Jul 2020
- Primary completion15 Feb 2022
- Study completion15 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Pelvic Organ ProlapseStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled non-inferiority trial
- Masking
- Triple blind
- Who is masked
- Care provider, Investigator, Outcomes assessor
- Enrolment
- 123 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matthew Barber, MD, MHS, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04329715
- Sponsor's protocol ID
- Pro00104389
- Acronym
- EVeRLAST
- Status last verified
- Feb 2022
- First submitted
- 30 Mar 2020
- Last updated
- 8 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Brubaker L, Barber MD, Nygaard I, Nager CW, Varner E, Schaffer J, Visco A, Meikle S, Spino C; Pelvic Floor Disorders Network. Quantification of vaginal support: are continuous summary scores better than POPQ stage? Am J Obstet Gynecol. 2010 Nov;203(5):512.e1-6. doi: 10.1016/j.ajog.2010.06.071. Epub 2010 Aug 21.
PubMed 20728072Tomioka K, Iwamoto J, Saeki K, Okamoto N. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study. J Epidemiol. 2011;21(6):459-65. doi: 10.2188/jea.je20110003. Epub 2011 Sep 24.
PubMed 21946625O'Shea M, Siddiqui NY, Truong T, Erkanli A, Barber MD. Standard Restrictions vs Expedited Activity After Pelvic Organ Prolapse Surgery: A Randomized Clinical Trial. JAMA Surg. 2023 Aug 1;158(8):797-805. doi: 10.1001/jamasurg.2023.1649.
PubMed 37256578
Study at a glance
From the registry record, last updated by the sponsor on 8 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse
- ClinicalTrials.gov ID
- NCT04329715
- Acronym / sponsor ID
- EVeRLAST / Pro00104389
- Conditions
- Pelvic Organ Prolapse
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 123 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 15 Feb 2022 (actual)
- Study completion
- 15 Feb 2022 (actual)
- First posted
- 1 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the EVeRLAST study is to determine whether expedited resumption of postoperative activity levels is non-inferior to standard activity restrictions with respect to short-term anatomic prolapse outcomes. We hypothesize that immediate resumption of physical activities as tolerated will result in noninferior surgical outcomes following prolapse surgery when compared to standard postoperative activity restrictions.
Participants will be enrolled and randomized at their preoperative clinic visit to one of two treatment arms:
Arm 1: Standard instructions (no heavy lifting over 10lbs for 6 weeks; return to work at 4 weeks for sedentary work and 6 weeks for manual labor) Arm 2: Liberal instructions (no restrictions; resume activities and work as soon as able)
We will also collect subjective and objective measures of pre- and postoperative physical activity, through the use of patient-reported physical activity assessments and wrist-worn accelerometers. Accelerometer data will be collected at the preoperative, 2-week-postoperative, and 6-week-postoperative time points. Accelerometer data will also be used to calculate time to resumption of normal activities, defined as time at which a patient resumes greater than 90% of her baseline preoperative level of physical activity. We will additionally be collecting data on relevant patient-reported outcomes of pelvic floor symptom severity, health-related quality of life measures, postoperative pain, time to return to work (where relevant), and patient global impression of improvement. Postoperative anatomic assessments will be performed at 6 weeks and 3 months postoperatively by blinded study personnel
Detailed description
Specific aim 1: Determine if liberal (ad lib) resumption of postoperative activity levels is non-inferior to standard restrictions with regards to short-term anatomic and symptomatic outcome, as measured by maximum pelvic organ prolapse support loss ('SLmax') and the Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months. (Co-primary outcome)
Specific aim 2: Compare postoperative "Recovery Time" and physical function between women instructed to resume their activity levels ad lib versus women instructed to restrict activity levels. "Recovery Time," defined as the postoperative day at which the patient resumes 90% of her baseline activity levels will be objectively measured using the Actigraph accelerometer.8 ,9 Physical function will be measured with the 6-minute walk, chair stand tests, and through patient-reported outcome measures. (exploratory outcome)
Specific aim 3: Compare timing of return-to-work and health-related QOL in women instructed to resume activity levels and return to work ad lib versus restrict their activity levels (exploratory outcome)
Eligible participants will first be briefly explained regarding the research study. If interested, will then complete the informed consent process. She will first be asked to complete the International Physical Activity Short Form to confirm study eligibility. For study eligibility, participants must at least report a baseline of 725 MET-minutes per week of physical activity according to the IPAQ-SF, which is consistent with the lowest quartile of activity among elderly women. If she reports greater than 725 MET-minutes per week of physical activity, she will undergo the remainder of baseline assessments. If she reports less than 725 MET-minutes per week of physical activity, she will be explained that she does not meet the activity level criteria for completion of the study at this time. She will then be asked to complete a series of baseline questionnaires (demographics, past medical history, POPDI, AAS, PROMIS, PFDI, PFIQ). She will also undergo a baseline POPQ exam and tests of physical function, including the 6-minute walk test and chair stand test.
A sealed envelope will then be opened by the research coordinator (or study investigator) in front of the patient indicating the patient's study allocation. The packet will also include an accelerometer which the patient will be instructed to wear for a 7-day period preoperatively. However, to ensure that participants are not given an accelerometer too far in advance from her surgery (as at times surgery may be scheduled remotely from the initial decision to proceed with surgery which would potentially result in too many accelerometers being out of circulation), the envelope containing study allocation and accelerometers may alternatively be provided at the preoperative "Surgical Workup" visit once the surgery is scheduled and at a date no greater than 3 weeks from the planned surgery. If a participant will be undergoing surgery at an interval greater than 1 week from the initial receipt of the accelerometer, she will only be required to wear the accelerometer for 1 week prior to the surgery. Patients will be given an opportunity to ask any questions regarding postoperative activity instructions to research personnel or nurses at the time of study enrollment and at any point prior to her surgery. Patients will be notified, prior to providing consent, that her primary surgeon will remain blinded as to her treatment allocation until completion of her study participation.
Any questions related to surgical recovery which arise preoperatively will be addressed by nurses and research personnel not involved in the patient's intraoperative decision-making. Postoperatively, fellow and attending surgeons will only be unblinded if necessary to address any acute postoperative issues. Patients will also be provided with a duplicate set of postoperative set of activity instructions on the day of her surgery upon discharge which will be entered in the patient's electronic chart by study personnel on the day of her surgery as a modification to the standard postoperative discharge instructions.
The patient will wear the activity tracker for 6 weeks postoperatively. At the 1-week postoperative time point, patient reminder phone calls will be made to remind the patient to wear and charge the activity tracker (whose battery life is 25 days). She will also be asked to provide a count of the number of narcotic pills she has left remaining at this time. She will follow-up for a routine postoperative visit with her primary surgeon at which point a routine 6-week postoperative POPQ will be performed. Accelerometers will be returned at this visit.
She will then follow up for a separate research visit at 3 months postoperatively. At this time, the patient will complete all follow-up activity, symptom, and HRQOL questionnaires including the: Activities Assessment Scale, Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and the PROMIS short form subscales of physical function, anxiety, depression, fatigue, satisfaction with social role, and pain interference. A six-minute walk and chair stand test will be administered by trained research personnel in the clinic. She will additionally be inquired regarding timing of return to work. A POPQ will also be performed at this time by a blinded provider NOT involved in the patient's index surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized controlled non-inferiority trial
| Arm | Type | Receives |
|---|---|---|
| Expedited instructions | Experimental | Behavioral: Expedited postoperative activity instructions |
| Restricted instructions | Active comparator | Behavioral: Standard postoperative activity restructions |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Stage II-IV pelvic organ prolapse
- Bothersome bulge symptoms
- At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form
- English-speaking
- Undergoing treatment of prolapse
Key exclusion criteria (3 listed)
- Enrollment in another research study of pelvic organ prolapse
- Concomitant non-urogynecologic surgery
- Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Expedited postoperative activity instructionsAd lib postoperative activity and return to work recommendations | Behavioural | Expedited instructions |
| Standard postoperative activity restructionsStandard conservative postoperative activity and return to work recommendations | Behavioural | Restricted instructions |
Primary outcome
Maximum support loss "SLMax"
Time frame: 3 months
Most distal point of pelvic organ support (in centimeters) based on Pelvic Organ Prolapse Quantification system
Prolapse symptoms
Time frame: 3 months
Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months
11 secondary outcomes
Recovery time
Time frame: 6 weeks
Health related quality of life (HRQOL)
Time frame: 3 months
Physical function
Time frame: 3 months
Physical function
Time frame: 3 months
Time to return to work
Time frame: 3 months
Postoperative opioid requirement
Time frame: 2 weeks
Pelvic floor symptom severity
Time frame: 3 months
Pelvic floor symptom severity
Time frame: 3 months
Functional activity
Time frame: 3 months
Patient satisfaction
Time frame: 3 months
Postoperative morbidity
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Mar 2022.
- Background: PubMed 20728072Brubaker L, Barber MD, Nygaard I, Nager CW, Varner E, Schaffer J, Visco A, Meikle S, Spino C; Pelvic Floor Disorders Network. Quantification of vaginal support: are continuous summary scores better than POPQ stage? Am J Obstet Gynecol. 2010 Nov;203(5):512.e1-6. doi: 10.1016/j.ajog.2010.06.071. Epub 2010 Aug 21.
- Background: PubMed 21946625Tomioka K, Iwamoto J, Saeki K, Okamoto N. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study. J Epidemiol. 2011;21(6):459-65. doi: 10.2188/jea.je20110003. Epub 2011 Sep 24.
- Derived from this study: PubMed 37256578O'Shea M, Siddiqui NY, Truong T, Erkanli A, Barber MD. Standard Restrictions vs Expedited Activity After Pelvic Organ Prolapse Surgery: A Randomized Clinical Trial. JAMA Surg. 2023 Aug 1;158(8):797-805. doi: 10.1001/jamasurg.2023.1649.
- Individual participant dataSharing planned: No
Related trials for Pelvic Organ Prolapse
Active, not recruitingObservational study
Return to Physical Activity After Retropublic Transvaginal Sling and Laparoscopic Sacrocolpopexy
Stress Urinary Incontinence, Pelvic Organ Prolapse
Active, not recruitingObservational study
i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)
Pelvic Organ Prolapse, Genital Prolapse
Recruiting
Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)
Pelvic Organ Prolapse (POP), Synthetic Mesh
Recruiting
Pelvic Floor Muscle Training During Pregnancy
Urinary Incontinence, Anal Incontinence
Not yet recruiting
Perineal Protection Device for Reducing Perineal Trauma During Vaginal Delivery in First-time Mothers: a Multicenter Randomized Controlled Trial
Pelvic Floor Dysfunction, Perineal Laceration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthew Barber, MD, MHS principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Expedited postoperative activity instructions and Standard postoperative activity restructions in people with Pelvic Organ Prolapse, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum support loss "SLMax" (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04329715, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2022.